세계 제약·바이오·건강기능 산업 전문 전시회

Deucravacitinib is a tyrosine kinase 2 (TYK2) inhibitor indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. It binds to the regulatory domain of TYK2 with high selectivity to this therapeutic target. This selectivity towards TYK2 may lead to an improved safety profile of Deucravacitinib, as nonselective JAK inhibitors are associated with a range of adverse effects such as altered cholesterol and triglyceride levels and liver and kidney dysfunction. It is approved in USA, Europe, and few countries of Latin America and Southeast Asia, including Japan and South Korea. Currently, it is under clinical trials for Sjogren Syndrome, Psoriatic Arthritis and Systemic Lupus Erythematosus. We are ready to provide its lab validated samples along with CoA.